Response

We appreciate di Val Cervo et al's comments on our article about the role of miR-106b in repressing the ubiquitin ligase, Itch, to result in increases in the levels of p73 in CLL.1 

The ability of microRNA to interact with and suppress endogenous targets likely depends on the cellular context in which it is expressed. Associations of microRNAs and their targets determined in one cell type may not predict their association in another cell type. This concept is illustrated by several examples: miRs-17∼19b targeted Bim in one lymphoma cell line but not another2 ; miR-29b targeted DNMT3a/b in lung3  but not in other cell types4 ; miR26a targeted EZH2 efficiently in leukemia but minimally in embryonic kidney cells.5  Our work demonstrated that ectopic expression of miR-106b in quiescent CLL cells resulted in a repression of Itch (n = 4) that was mechanistically associated with an increase in p73 levels. In contrast, over-expression of miR-106b in H1299 lung cancer cells did not decrease the levels of Itch protein (D.S., unpublished observations, June 2006). However, the levels of Itch protein were readily reduced in response to LBH589 suggesting that mechanisms unrelated to mir-106b were likely to regulate Itch in this cell line. Similarly, the findings presented in the letter show that miR-106 did not repress Itch in Saos2 osteosarcoma or HEK293T embryonic kidney cells. This result likely reflects the role of cellular context in determining miRNA and target gene associations, and may not recapitulate the actions of miR-106b in primary, quiescent CLL cells. In addition, miRNAs are likely to share a reciprocal relationship with their targets in individual cell types.6  miR-106b is over-expressed in several solid tumors and cell lines, shares a reciprocal relation with p21,7,8  and represses p21 in such cells.8  However, in CLL, miR-106b and its host gene Mcm7 were epigenetically silenced, shared a reciprocal relation with Itch, not p21, and targeted Itch, not p21, in this disease.1 

We demonstrated a 1.4- to 4-fold increase in the levels of mir-106b in 12 of 19 CLL samples exposed to LBH589 (Figure 2A1 ; P < .01, paired t test), whereas the cumulative data in Table 1 indicate an increase in miR-106b levels in 16 of 23 samples evaluated.1  di Val Cervo et al demonstrated similar inductions in the levels of miR-106b upon 10 nM LBH exposure but statistically compared the induction of miR-106b with that of p73, DNp73 and miR34a, indicating that the objective of the 2 experiments differed considerably. In addition, we reported that transcriptional induction accounted for increases in p73 in a fraction of the samples evaluated (7/20). This suggests the existence of additional mechanisms that must account for the observed increases in p73 protein in samples that do not demonstrate a transcriptional induction. Finally, the catalytic activity of Itch was unaffected by caspase cleavage.9  Both full-length and the cleaved fragment of Itch were efficient at ubiquitilating their physiologic substrates.9  Consequently, caspase cleavage of Itch is unlikely to be unrelated mechanistically to the LBH-induced signaling pathway that results in increases in p73 protein, as described in our work.

The comments pertaining to miR-34a refer to work conducted by others10  and may need to be addressed separately.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Dr Deepa Sampath, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030. e-mail: [email protected]

1
Sampath
 
D
Calin
 
GA
Puduvalli
 
VK
et al. 
Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation.
Blood
2009
, vol. 
113
 (pg. 
3744
-
3753
)
2
Inomata
 
M
Tagawa
 
H
Guo
 
YM
Kameoka
 
Y
Takahashi
 
N
Sawada
 
K
MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes.
Blood
2009
, vol. 
113
 (pg. 
396
-
402
)
3
Fabbri
 
M
Garzon
 
R
Cimmino
 
A
et al. 
MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B.
Proc Natl Acad Sci U S A
2007
, vol. 
104
 (pg. 
15805
-
15810
)
4
Sinkkonen
 
L
Hugenschmidt
 
T
Berninger
 
P
et al. 
MicroRNAs control de novo DNA methylation through regulation of transcriptional repressors in mouse embryonic stem cells.
Nat Struct Mol Biol
2008
, vol. 
15
 (pg. 
259
-
267
)
5
Sander
 
S
Bullinger
 
L
Klapproth
 
K
et al. 
MYC stimulates EZH2 expression by repression of its negative regulator miR-26a.
Blood
2008
, vol. 
112
 (pg. 
4202
-
4212
)
6
Varambally
 
S
Cao
 
Q
Mani
 
RS
et al. 
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer.
Science
2008
, vol. 
322
 (pg. 
1695
-
1699
)
7
Ivanovska
 
I
Ball
 
AS
Diaz
 
RL
et al. 
MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression.
Mol Cell Biol
2008
, vol. 
28
 (pg. 
2167
-
2174
)
8
Petrocca
 
F
Visone
 
R
Onelli
 
MR
et al. 
E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer.
Cancer Cell
2008
, vol. 
13
 (pg. 
272
-
286
)
9
Rossi
 
M
Inoue
 
S
Walewska
 
R
et al. 
Caspase cleavage of Itch in chronic lymphocytic leukemia cells.
Biochem Biophys Res Commun
2009
, vol. 
379
 (pg. 
659
-
664
)
10
Zenz
 
T
Mohr
 
J
Eldering
 
E
et al. 
MiR-34a as part of the chemotherapy resistance network in chronic lymphocytic leukemia.
Blood
2009
, vol. 
113
 (pg. 
3801
-
3808
)

National Institutes of Health

Sign in via your Institution